New Antitumor Drug – PDL1 ADC
Antibody-drug conjugates (ADCs) in antitumor therapy, also known as “biological missiles,” are a new type of drug that combines targeting and antitumor activity. By linking cytotoxic drugs to targeted drugs, when the targeted drug acts on the corresponding target, the drug enters the tumor cells through phagocytosis, causing lysis and releasing the cytotoxic drug to … Read more